Brookline Capital Markets Predicts Medicus Pharma Q1 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings estimates for Medicus Pharma in a report released on Tuesday, March 31st. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.20) per share for the quarter. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.10) EPS.

Other research analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a report on Thursday, March 19th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medicus Pharma has an average rating of “Hold” and an average target price of $23.50.

Medicus Pharma Trading Up 6.4%

Shares of NASDAQ MDCX opened at $0.45 on Wednesday. The stock has a market cap of $11.42 million, a PE ratio of -0.16 and a beta of 1.16. Medicus Pharma has a 12-month low of $0.37 and a 12-month high of $8.94. The company has a 50-day moving average of $0.90 and a 200 day moving average of $1.67.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.50).

Institutional Investors Weigh In On Medicus Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of MDCX. Jane Street Group LLC acquired a new position in Medicus Pharma in the 2nd quarter valued at about $41,000. Osaic Holdings Inc. increased its holdings in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after buying an additional 9,000 shares during the last quarter. Brave Asset Management Inc. acquired a new stake in shares of Medicus Pharma during the 3rd quarter worth approximately $46,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Medicus Pharma during the 3rd quarter valued at approximately $59,000. Finally, Private Advisor Group LLC raised its position in shares of Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.